When people ask, "Is so-and-so the next Enron?" they usually don't make a strong case that "so-and-so" is much like Enron. Rather, "It's involves some accounting mumbo jumbo, so let's call it Enron." Which brings us to Valeant Pharmaceuticals, who hasn't had a good day. A report from Citron Research claims that the company is […]